As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Evotec SE. The largest reported stake is Excalibur LuxCo SARL's, at 9.99%. 8 filings are on record since October 29, 2025 (Schedule 13D/A, October 29, 2025).
Sell to companies like Evotec SE? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Mubadala Investment Company PJSC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-14
- · Holder: MAK Capital Fund LP · Percent: 7.1% · SCHEDULE 13D/A
- · Holder: MAK Capital Fund LP intent stated · Percent: 7% · SCHEDULE 13D/A
- · Holder: MAK Capital Fund LP · Percent: 7% · SCHEDULE 13D
- · Holder: Novo Holdings A/S · Percent: 0% · SCHEDULE 13G/A
Evotec SE has 8 Schedule 13D or 13G filings on record since 2025-10-29. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 MAK Capital Fund LP
In furtherance of the Purpose of Transaction, the Reporting Persons sent a letter to the Issuer's Supervisory & Management Board, which letter is attached as Exhibit 2 to this Amendment 1.From Item 4 of the SCHEDULE 13D/A filed 2026-04-06
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Excalibur LuxCo SARL | 9.99% | 17,730,913 | SCHEDULE 13D/A, 2025-10-29 | 2025-10-27 |
| MAK Capital Fund LP | 7.1% | 12,681,898 | SCHEDULE 13D/A, 2026-05-01 | 2026-04-29 |
| Novo Holdings A/S | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Mubadala Investment Company PJSC | 0% | 0 | SCHEDULE 13D/A, 2026-10-14 | 2026-10-09 |
Holding shares or following this stake? See who's behind Evotec SE and the warning signs.
Free to see. No signup.
Keep reading
More on Evotec SE and the records around it.
Evotec SE elsewhere on the record
Companies that share a holder
- Mubadala Investment Company PJSC also filed stake reports on 5 other companies: GLOBALFOUNDRIES Inc. (Aug 2026), Blue Owl Technology Finance Corp. (Feb 2026), RECURSION PHARMACEUTICALS, INC. (Dec 2025)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), ClearPoint Neuro, Inc. (May 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
Watch Evotec SE
Get an email when Evotec SE files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Evotec SE?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Evotec SE: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evotec SE covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Mubadala Investment Company PJSC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-10-14 |
| Mamoura Diversified Global Holding PJSC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-10-14 |
| Mubadala Technology Investments LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-10-14 |
| ATIC Second International Investment Company LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-10-14 |
| Ninety Fourth Investment Company LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-10-14 |
The latest filing identifies Evotec SE by CUSIP 30050E105 and gives its principal executive office as Manfred Eigen Campus, Essener Bogen 7, Hamburg (SCHEDULE 13D/A, 2026-10-14).
Source of funds (Item 3)
The information set forth in or incorporated by reference in Item 2, Item 4, Item 5 and Item 6 of this Statement is herein incorporated by reference into this Item 3.Mubadala Investment Company PJSC, SCHEDULE 13D/A, 2026-10-14
Purpose of Transaction (Item 4)
MAK Capital Fund LP
SCHEDULE 13D A/2 Amendment 2 This Amendment 2 to the statement on Schedule 13D ("Amendment 2") to the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") by the MAK Capital Fund LP, a Bermuda limited partnership ("MAK Fund"), MAK Capital One L.L.C., a Delaware limited liability company ("MAK Capital"), as the investment manager of MAK Fund and Michael A. Kaufman, as Managing Member of MAK Capital (collectively with MAK Fund and MAK Capital, "MAK" and together MAK Fund and MAK Capital collectively the "Reporting Persons") on March 30, 2026 (the "Original Schedule 13D") and amendment number 1 thereto filed on April 6, 2026 ("Amendment 1" and together with this Amendment 2 and the Original Schedule 13D, "Schedule 13D") amends and supplements the Original Schedule 13D and Amendment 1 and relates to to the ordinary shares, no par value per share (the "Shares") of EVOTEC SE (the "Issuer") beneficially owned by the Reporting Persons. The principal executive offices of the Issuer are located at Essener Bogen 7, Hamburg, GERMANY , 22419. Except as set forth herein in this Amendment 2, the Schedule 13D is unmodified. In furtherance of the Purpose of Transaction, MAK Fund and Issuer signed a cooperation agreement on April 29, 2026. Under the terms, described further in the press release by Issuer filed with the SEC as Exhibit 99.1 to Issuer's Current Report on Form 6-K on April 30, 2026, Issuer will nominate Dr. Wolfgang Hofmann for election as an independent …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-01; the filing has the rest
Mubadala Investment Company PJSC
The information set forth in Item 3, Item 5 and Item 6 of this Statement is herein incorporated by reference into this Item 4. Pursuant to that certain Investment Agreement, dated October 12, 2020, by and between ATIC Second International Investment Company and the Issuer, ATIC Second International Investment Company purchased 9,182,652 Ordinary Shares issued by the Issuer by way of a private placement (the "Private Placement") for aggregate consideration of approximately EUR200 million. On November 8, 2021, in connection with the Closing of the Issuer's initial public offering of its ADSs, ATIC Second International Investment Company purchased an aggregate of 4,597,701 ADSs, representing 2,298,850.5 Ordinary Shares at a price of $21.75 per ADS, which was the public offering price per ADS. The Reporting Persons have acquired the Shares reported herein for investment purposes. On July 29, 2022, ATIC Second International Investment Company transferred all of its 9,182,652 Ordinary Shares and 4,597,701 ADSs to Ninety Fourth Investment Company, a wholly owned subsidiary of Mamoura Diversified Global Holding, as part of an internal reorganization. As a result, Mubadala Technology Investments and ATIC Second International Investment Company ceased to beneficially own any Ordinary Shares. The beneficial ownership of Mubadala Investment Company and Mamoura Diversified Global Holding was not affected by the transfer. On May 25, 2026 Ninety Fourth Investment Company converted all …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-10-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-29 | Excalibur LuxCo SARL | 9.99% | SCHEDULE 13D/A |
| 2025-11-14 | Novo Holdings A/S | 5.3% | SCHEDULE 13G/A |
| 2026-01-16 | MAK Capital Fund LP | 5.3% | SCHEDULE 13G |
| 2026-02-17 | Novo Holdings A/S | 0% | SCHEDULE 13G/A |
| 2026-03-30 | MAK Capital Fund LP | 7% | SCHEDULE 13D |
| 2026-04-06 | MAK Capital Fund LP intent stated | 7% | SCHEDULE 13D/A |
| 2026-05-01 | MAK Capital Fund LP | 7.1% | SCHEDULE 13D/A |
| 2026-10-14 | Mubadala Investment Company PJSC | 0% | SCHEDULE 13D/A |
Questions about who owns Evotec SE
Who owns Evotec SE?
On this page, 2 holders' latest ownership filings report 5% or more of Evotec SE: Excalibur LuxCo SARL (9.99%, Schedule 13D/A, filed 2025-10-29) and MAK Capital Fund LP (7.1%, Schedule 13D/A, filed 2026-05-01).
Who are the largest shareholders of Evotec SE?
By the share each holder's latest filing reports, the largest holders of Evotec SE on this page are Excalibur LuxCo SARL (9.99%) and MAK Capital Fund LP (7.1%).
When did Excalibur LuxCo SARL buy into Evotec SE?
The filings give report dates, not purchase dates. The earliest filing from Excalibur LuxCo SARL on this page is the Schedule 13D/A, filed 2025-10-29, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Evotec SE. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.